Abuirmeileh A, Harkavyi A, Kingsbury A, Lever R, Whitton PS (2008) The CRF-like peptide urocortin produces a long-lasting recovery in rats made hemiparkinsonian by 6-hydroxydopamine or lipopolysaccharide. J Neurol Sci 271:131–136

Agarwal S, Mishra P, Shivange G, Kodipelli N, Moros M, de La Fuente JM, Anindya R (2015) Citrate-capped gold nanoparticles for the label-free detection of ubiquitin C-terminal hydrolase-1. Analyst 140:1166–1173

Azeem A, Talegaonkar S, Negi LM, Ahmad FJ, Khar RK, Iqbal Z (2012) Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. Int J Pharm 422:436–444

Barbosa MT, Caramelli P, Maia DP, Cunningham MC, Guerra HL, Lima-Costa MF, Cardoso F (2006) Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambuí study). Mov Disord 21:800–808

Bonina F, Puglia C, Rimoli MG, Melisi D, Boatto G, Nieddu M, Calignano A, La Rana G, De Caprariis P (2003) Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies. J Drug Target 11:25–36

Bortolanza M, Bariotto-dos-Santos KD, dos-Santos-Pereira M, da-Silva CA, Del-Bel EA (2016) Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson’s Disease. Neurotox Res 30:88

Bortolanza M, Cavalcanti-Kiwiatkoski R, Padovan-Neto FE, da-Silva CA, Mitkovski M, Raisman-Vozari R, Del-Bel E (2015a) Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson’s disease. Neurobiol Dis 73:377–387

Bortolanza M, Padovan-Neto FE, Cavalcanti-Kiwiatkoski R, Dos Santos-Pereira M, Mitkovski M, Raisman-Vozari R, Del-Bel E (2015b) Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson’s disease induced by L-DOPA? Philos Trans R Soc Lond B Biol Sci 5(1672):370

Chaturvedi M, Molino Y, Sreedhar B, Khrestchatisky M, Kaczmarek L (2014) Tissue inhibitor of matrix metalloproteinases-1 loaded poly(lactic-co-glycolic acid) nanoparticles for delivery across the blood-brain barrier. Int J Nanomed 9:575–588

Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC (2007) Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337:1–24

Da Rocha Lindner G, Bonfanti Santos D, Colle D, Gasnhar Moreira EL, Daniel Prediger R, Farina M, Khalil NM, Mara Mainardes R (2015) Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism. Nanomedicine (Lond) 10:1127–1138

De Giglio E, Trapani A, Cafagna D, Sabbatini L, Cometa S (2011) Dopamine-loaded chitosan nanoparticles: formulation and analytical characterization. Anal Bioanal Chem 400:1997–2002

Demirel M, Yazan Y, Müller RH, Kiliç F, Bozan B (2001) Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul 18:359–371

Di Gioia S, Trapani A, Mandracchia D, De Giglio E, Cometa S, Mangini V, Arnesano F, Belgiovine G, Castellani S, Pace L, Lavecchia MA, Trapani G, Conese M, Puglisi G, Cassano T (2015) Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles. Eur J Pharm Biopharm 94:180–193

Dos-Santos-Pereira M, da-Silva CA, Guimarães FS, Del-Bel EA (2016) Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action. Neurobiol Dis 94:179–195

Drexler E (1986) Engines of construction. Engines of creation: the coming era of nanotechnology. Anchor, New York, pp 3–17

Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P, Sivieri E, Lain F, Menegatti E, Morari M, Cortesi R (2008) Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res 25:1521–1530

Esposito E, Mariani P, Ravani L, Contado C, Volta M, Bido S, Drechsler M, Mazzoni S, Menegatti E, Morari M, Cortesi R (2012) Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study. Eur J Pharm Biopharm 80:306–314

Feynman R (1959). RE: Plenty of room at the bottom

Fletcher AM, Kowalczyk TH, Padegimas L, Cooper MJ, Yurek DM (2011) Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor. Neuroscience 194:220–226

Fonseca-Santos B, Gremião MP, Chorilli M (2015) Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine 10:4981–5003

Gambaryan PY, Kondrasheva IG, Severin ES, Guseva AA, Kamensky AA (2014) Increasing the efficiency of parkinson’s disease treatment using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA delivery system. Exp Neurobiol 23:246–252

Garbayo E, Ansorena E, Blanco-Prieto MJ (2013) Drug development in Parkinson’s disease: from emerging molecules to innovative drug delivery systems. Maturitas 76(3):272–278

Gomes MZ, Raisman-Vozari R, Del Bel EA (2008) A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res 1203:160–169

González-Aparicio R, Moratalla R (2014) Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV-1 receptor in a mouse model of Parkinson s disease. Neurobiol Dis 62:416–425

Gulati N, Nagaich U, Saraf S (2014) Fabrication and in vitro characterization of polymeric nanoparticles for Parkinson’s therapy: a novel approach. Braz J Pharm Sci 50(4):869–876

Hamidi M, Azadi A, Rafiei P, Ashrafi H (2013) A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach. Crit Rev Ther Drug Carrier Syst 30:435–467

Haney MJ, Zhao Y, Li S, Higginbotham SM, Booth SL, Han HY, Vetro JA, Mosley RL, Kabanov AV, Gendelman HE, Batrakova EV (2011) Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells. Nanomedicine (Lond) 6:1215–1230

Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM (2009) Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem 284:6972–6981

Henriksen T (2014) Clinical insights into use of apomorphine in Parkinson’s disease: tools for clinicians. Neurodegener Dis Manag 4:271–282

Herrán E, Requejo C, Ruiz-Ortega JA, Aristieta A, Igartua M, Bengoetxea H, Ugedo L, Pedraz JL, Lafuente JV, Hernández RM (2014) Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease. Int J Nanomedicine 9:2677–2687

Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X (2011) Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson’s disease. Int J Pharm 415:273–283

Huang R, Han L, Li J, Ren F, Ke W, Jiang C, Pei Y (2009) Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med 11(9):754–763

Hwang TL, Lin YK, Chi CH, Huang TH, Fang JY (2009) Development and evaluation of perfluorocarbon nanobubbles for apomorphine delivery. J Pharm Sci 98:3735–3747

Iv M, Telischak N, Feng D, Holdsworth SJ, Yeom KW, Daldrup-Link HE (2015) Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors. Nanomedicine 10(6):993–1018

Jafarieh O, Md S, Ali M, Baboota S, Sahni JK, Kumari B, Bhatnagar A, Ali J (2014) Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev Ind Pharm, pp 1–8

Joshi N, Basak S, Kundu S, De G, Mukhopadhyay A, Chattopadhyay K (2015) Attenuation of the early events of α-synuclein aggregation: a fluorescence correlation spectroscopy and laser scanning microscopy study in the presence of surface-coated Fe3O4 nanoparticles. Langmuir 31:1469–1478

Kaye CM, Nicholls B (2000) Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 39:243–254

Kim DS, Palmiter RD, Cummins A, Gerfen CR (2006) Reversal of supersensitive striatal dopamine D1 receptor signaling and extracellular signal-regulated kinase activity in dopamine-deficient mice. Neuroscience 137:1381–1388

Ksendzovsky A, Walbridge S, Saunders RC, Asthagiri AR, Heiss JD, Lonser RR (2012) Convection-enhanced delivery of M13 bacteriophage to the brain. J Neurosurg 117:197–203

Kulkarni AD, Vanjari YH, Sancheti KH, Belgamwar VS, Surana SJ, Pardeshi CV (2015) Nanotechnology-mediated nose to brain drug delivery for Parkinson’s disease: a mini review. J Drug Target 1-14

Kura AU (2014) Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson’s disease model. Int J Mol Sci 15(4):5916–5927

Kura AU, Hussein Al Ali SH, Hussein MZ, Fakurazi S, Arulselvan P (2013) Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. Int J Nanomedicine 8:1103–1110

Lee TJ, Haque F, Shu D, Yoo JY, Li H, Yokel RA, Horbinski C, Kim TH, Kim SH, Kwon CH, Nakano I, Kaur B, Guo P, Croce CM (2015) RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. Oncotarget 6(17):14766–14776

López T, Bata-García JL, Esquivel D, Ortiz-Islas E, Gonzalez R, Ascencio J, Quintana P, Oskam G, Alvarez-Cervera FJ, Heredia-López FJ, Góngora-Alfaro JL (2011) Treatment of Parkinson’s disease: nanostructured sol-gel silica-dopamine reservoirs for controlled drug release in the central nervous system. Int J Nanomedicine 6:19–31

Malvindi MA, Di Corato R, Curcio A, Melisi D, Rimoli MG, Tortiglione C, Tino A, George C, Brunetti V, Cingolani R, Pellegrino T, Ragusa A (2011) Multiple functionalization of fluorescent nanoparticles for specific biolabeling and drug delivery of dopamine. Nanoscale 3:5110–5119

Marconi S, Zwingers T (2014) Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson’s disease. Eur Rev Med Pharmacol Sci 18:1879–1882

Martinez AA, Morgese MG, Pisanu A, Macheda T, Paquette MA, Seillier A, Cassano T, Carta AR, Giuffrida A (2015) Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Neurobiol Dis 74:295–304

Md S, Haque S, Fazil M, Kumar M, Baboota S, Sahni JK, Ali J (2014) Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. Expert Opin Drug Deliv 11:827–842

Mercante LA, Pavinatto A, Iwaki LE, Scagion VP, Zucolotto V, Oliveira ON, Mattoso LH, Correa DS (2015) Electrospun polyamide 6/poly(allylamine hydrochloride) nanofibers functionalized with carbon nanotubes for electrochemical detection of dopamine. ACS Appl Mater Interfaces 7:4784–4790

Mittal D, Md S, Hasan Q, Fazil M, Ali A, Baboota S, Ali J (2014) Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(264–9):W64

Mustafa G, Ahuja A, Al Rohaimi AH, Muslim S, Hassan AA, Baboota S, Ali J (2015) Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization. Expert Rev Neurother 15:695–710

Nyholm D (2006) Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin Pharmacokinet 45:109–136

Olanow CW (2004) The scientific basis for the current treatment of Parkinson’s disease. Annu Rev Med 55:41–60

Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361:1268–1278

Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel E (2009) Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson’s disease. Neuroscience 159(3):927–935

Padovan-Neto FE, Ferreira NR, de Oliveira-Tavares D, de Aguiar D, da Silva CA, Raisman-Vozari R, Del Bel E (2013) Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression. Neurosci Lett 541(29):126–131

Padovan-Neto FE, Cavalcanti-Kiwiatkoviski R, Carolino RO, Anselmo-Franci J, Del Bel E (2015) Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. Neuropharmacology 89:87–99

Pahuja R, Seth K, Shukla A, Shukla RK, Bhatnagar P, Chauhan LK, Saxena PN, Arun J, Chaudhari BP, Patel DK, Singh SP, Shukla R, Khanna VK, Kumar P, Chaturvedi RK, Gupta KC (2015) Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats. ACS Nano 9:4850–4871

Pardeshi CV, Belgamwar VS, Tekade AR, Surana SJ (2013a) Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med 24:2101–2115

Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR, Surana SJ (2013b) Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach. Drug Deliv 20:47–56

Park SJ, Song HS, Kwon OS, Chung JH, Lee SH, An JH, Ahn SR, Lee JE, Yoon H, Park TH, Jang J (2014) Human dopamine receptor nanovesicles for gate-potential modulators in high-performance field-effect transistor biosensors. Sci Rep 4:4342

Pathak K, Akhtar N (2016) Nose to Brain Delivery of nanoformulations for neurotherapeutics in Parkinson`s disease: defining the preclinical. Curr Drug Deliv, Clinical and toxicity issues. doi:10.2174/1567201813666160607123409

Patil GB, Surana SJ (2013) Fabrication and statistical optimization of surface engineered PLGA nanoparticles for naso-brain delivery of ropinirole hydrochloride: in vitro-ex vivo studies. J Biomater Sci Polym Ed 24:1740–1756

Perez-Lloret S, Rascol O (2011) Safety of rasagiline for the treatment of Parkinson’s disease. Expert Opin Drug Saf 10:633–643

Pillay S, Pillay V, Choonara YE, Naidoo D, Khan RA, Du Toit LC, Ndesendo VM, Modi G, Danckwerts MP, Iyuke SE (2009) Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Int J Pharm 382:277–290

Porras G, Berthet A, Dehay B, Li Q, Ladepeche L, Normand E, Dovero S, Martinez A, Doudnikoff E, Martin-Négrier ML, Chuan Q, Bloch B, Choquet D, Boué-Grabot E, Groc L, Bezard E (2012) PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest 122(11):3977–3989

Quinn JF, Whittaker MR, Davis TP (2015) Delivering nitric oxide with nanoparticles. J Control Release 205:190–205

Radad K, Gille G, Rausch WD (2005) Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s disease. Pharmacol Rep 57:701–712

Re F, Gregori M, Masserini M (2012) Nanotechnology for neurodegenerative disorders. Maturitas 73(1):45–51

Ruiz-DeDiego I, Mellstrom B, Vallejo M, Naranjo JR, Moratalla R (2015a) Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice. Biol Psychiatry 77(2):95–105

Ruiz-DeDiego I, Naranjo JR, Hervé D, Moratalla R (2015b) Dopaminergic regulation of olfactory type G-protein α subunit expression in the striatum. Mov Disord 30(8):1039–1049

Schapira AH (2013) Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol 26:395–400

Scognamiglio V (2013) Nanotechnology in glucose monitoring: advances and challenges in the last 10 years. Biosens Bioelectron 47:12–25

Shadab Md, Shadabul H, Mohammad F, Manish K, Sanjula B, Jasjeet K, Javed A (2014) Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. Expert Opin Drug Deliv 11(6):827–842

Sharma S, Lohan S, Murthy RSR (2013) Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm 40(7):869–878

Singh S, Sharma A, Robertson GP (2012) Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res 72:5663–5668

Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P (2005) Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 20:306–314

So RQ, Mcconnell GC, August AT, Grill WM (2012) Characterizing effects of subthalamic nucleus deep brain stimulation on methamphetamine-induced circling behavior in hemi-Parkinsonian rats. IEEE Trans Neural Syst Rehabil Eng 20:626–635

Solís O, Espadas I, Del-Bel EA, Moratalla R (2015) Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice. Neurobiol Dis 73:49–59

Spuch C, Saida O, Navarro C (2012) Advances in the treatment of neurodegenerative disorders employing nanoparticles. Recent Pat Drug Deliv Formul. 6(1):2–18

Stocchi F (2005) Optimising levodopa therapy for the management of Parkinson’s disease. J Neurol 252(4):43–48

Svendsen P, El-Galaly TC, Dybkær K, Bøgsted M, Laursen MB, Schmitz A, Jensen P, Johnsen HE (2015) The Application of Human Phase 0 Microdosing Trials - a Systematic Review and Perspectives. Leuk Lymphoma 57(6):1–28

Takuma K, Tanaka T, Takahashi T, Hiramatsu N, Ota Y, Ago Y, Matsuda T (2012) Neuronal nitric oxide synthase inhibition attenuates the development of L - DOPA -induced dyskinesia in hemi -Parkinsonian rats. Eur J Pharmacol 683:166–173

Tan JM, Foo JB, Fakurazi S, Hussein MZ (2015) Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes. Beilstein J Nanotechnol 6:243–253

Telischak IVM, Feng ND, Holdsworth SJ, Yeom KW, Daldrup-Link HE (2015) Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors. Nanomedicine (Lond) 10:993–1018

Trapani A, De Giglio E, Cafagna D, Denora N, Agrimi G, Cassano T, Gaetani S, Cuomo V, Trapani G (2011) Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int J Pharm 419:296–307

Tsai MJ, Huang YB, Wu PC, Fu YS, Kao YR, Fang JY, Tsai YH (2011) Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci 100:547–557

Watt KM, KC K, Cohen-Wolkowiez M (2013) Phase I Trials: First in Human. In: RENATO D LOPES RAH. (ed.) Understanding Clinical Research. Lange (Mc Graw Hill Education)

Wen Z, Yan Z, Hu K, Pang Z, Cheng X, Guo L, Zhang Q, Jiang X, Fang L, Lai R (2011) Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration. J Control Release 151:131–138

Xu Y, Deng Y, Qing H (2015) The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson’s disease. J Neurochem 135(1):4–18

Yang X, Zheng R, Cai Y, Liao M, Yuan W, Liu Z (2012) Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int J Nanomed 7:2077–2086